全文获取类型
收费全文 | 6676篇 |
免费 | 263篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 166篇 |
妇产科学 | 39篇 |
基础医学 | 794篇 |
口腔科学 | 196篇 |
临床医学 | 376篇 |
内科学 | 1555篇 |
皮肤病学 | 132篇 |
神经病学 | 498篇 |
特种医学 | 368篇 |
外科学 | 1176篇 |
综合类 | 29篇 |
预防医学 | 230篇 |
眼科学 | 75篇 |
药学 | 618篇 |
中国医学 | 13篇 |
肿瘤学 | 651篇 |
出版年
2022年 | 42篇 |
2021年 | 96篇 |
2020年 | 37篇 |
2019年 | 61篇 |
2018年 | 96篇 |
2017年 | 80篇 |
2016年 | 83篇 |
2015年 | 101篇 |
2014年 | 114篇 |
2013年 | 145篇 |
2012年 | 282篇 |
2011年 | 279篇 |
2010年 | 197篇 |
2009年 | 155篇 |
2008年 | 280篇 |
2007年 | 291篇 |
2006年 | 294篇 |
2005年 | 335篇 |
2004年 | 303篇 |
2003年 | 336篇 |
2002年 | 344篇 |
2001年 | 200篇 |
2000年 | 223篇 |
1999年 | 252篇 |
1998年 | 114篇 |
1997年 | 71篇 |
1996年 | 81篇 |
1995年 | 80篇 |
1994年 | 74篇 |
1993年 | 62篇 |
1992年 | 162篇 |
1991年 | 153篇 |
1990年 | 137篇 |
1989年 | 169篇 |
1988年 | 141篇 |
1987年 | 144篇 |
1986年 | 132篇 |
1985年 | 120篇 |
1984年 | 76篇 |
1983年 | 69篇 |
1982年 | 37篇 |
1981年 | 30篇 |
1980年 | 39篇 |
1979年 | 56篇 |
1978年 | 37篇 |
1977年 | 35篇 |
1972年 | 26篇 |
1971年 | 30篇 |
1970年 | 25篇 |
1968年 | 25篇 |
排序方式: 共有6970条查询结果,搜索用时 46 毫秒
1.
Marie Ohata Susumu Fujiwara Ai Yoshioka Hiroshi Nagai Shintaro Sugita Nozomi Yamano Yusuke Inoue Chikako Nishigori 《Pediatric dermatology》2019,36(6):997-998
Fibroblastic connective tissue nevus (FCTN) is a benign cutaneous mesenchymal lesion characterized by proliferation of CD34‐positive fibroblastic/myofibroblastic spindle‐shaped cells. We report a case of agminated FCTN on the right lower abdomen of a 1‐year‐old boy. 相似文献
2.
E Nakano T Yoshioka M Matsuda T Sonoda H Yano Y Ihara H Kuroda T Kishimoto T Sakurai K Uchida 《Hinyokika kiyo. Acta urologica Japonica》1990,36(5):635-642
Clinical effect of LM-001, a prostaglandin synthetic inhibitor developed from a drug delivery system, was evaluated in 54 patients with pain from urinary tract stones (stone pain) and 32 with vesical urgency after an operation on bladder or prostate. LM-001, felbinac ethyl incorporated in lipid microsphere, wes intravenously administered at the onset of stone pain or vesical urgency. Of 54 with stones and 32 with urgency, 53 and 29 were eligible for response, respectively. The symptoms improved or disappeared in some cases just after the administration and in the majority of patients within 15 minutes, in 49 of 53 patients with stone pain. Further, the effectiveness lasted over 24 hours in 26 of the 49 responding to this agent. On one hand, improvement or disappearance of vesical urgency was recognized in 25 of 29 patients, and the effectiveness was observed shortly after injection in 16 and lasted over 24 hours in 13 cases. Toxicities of this drug were investigated in 54 patients with stone pain and 32 with urinary urgency. Side effects consisted of pain at the injection site in 4, a slight fall of blood pressure in 1, slight visual disturbance in 1, body heat sensation in 1, leukocytosis in 3 and elevation of alkaline phosphatase in 1. These symptoms were transient and disappeared without use of any agent. LM-001 is concluded to be a useful drug for controlling stone pain and vesical urgency since an immediate effect, long durability and high response rates were obtained without severe side 相似文献
3.
4.
M Z Atassi M Yoshioka G S Bixler Jr 《Proceedings of the National Academy of Sciences of the United States of America》1989,86(17):6729-6733
Processing of a protein antigen into fragments is believed to be a prerequisite for its presentation by the antigen-presenting cell to the T cell. This model would predict that, in oligomeric proteins, T cells prepared with specificity for regions that are buried within subunit association surfaces should recognize the respective regions in vitro equally well on the isolated subunit or on the oligomer. Three hemoglobin (Hb) alpha-chain synthetic peptides, corresponding to areas that are situated either completely [alpha-(31-45)] or partially [alpha-(41-45) and alpha-(81-95)] within the interface between the alpha and beta subunits of Hb, and a fourth peptide representing a completely exposed area in tetrameric Hb were used as immunogens in SJL/J (H-2s) mice. Peptide-primed T cells were passaged in vitro with the respective peptide to obtain peptide-specific T-lymphocyte lines. T-cell clones were isolated from these lines by limiting dilution. T-cell lines and clones that were specific for buried regions in the subunit association surfaces recognized the free peptide and the isolated subunit but not the Hb tetramer. On the other hand, T cells with specificity against regions that are not involved in subunit interaction and are completely exposed in the tetramer recognized the peptide, the isolated subunit, and the oligomeric protein equally well. The responses of the T-cell lines and clones were major histocompatibility complex-restricted. Since the same x-irradiated antigen-presenting cells were employed, the results could not be attributed to differences or defects in Hb processing. The findings indicate that in vitro the native (unprocessed and undissociated) oligomeric protein was the trigger of major histocompatibility complex-restricted T-cell responses. 相似文献
5.
Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. 总被引:5,自引:0,他引:5
6.
PURPOSE: The aim of this study is (1) to develop a new method of risk classification for clinically localized prostate cancer; (2) to examine it in terms of compatibility with existing data such as nomograms; and (3) to compare it with existing risk-grouping methods. MATERIAL AND METHODS: The new grading system introduced here consists of three factors. The first is a prostate-specific antigen (PSA) of 4.1-10.0 ng/ml (score 0), 10.1-20.0 ng/ml (score 1), and >20.0 ng/ml (score 2). The second is a Gleason score (GS) of 6 (score 0), 7 (score 1), and 8-10 (score 2). The third is T classifications (UICC 2002) of T1c-T2a (score 0), T2b-T2c (score 1), and T3a (score 2). The sum of the three scores was named Prostate Risk Index (PRIX). Then, the compatibility of PRIX with the Partin Table, Kattan Nomogram, and Roach's formula was examined. At the same time, PRIX was compared with D'Amico, the National Comprehensive Cancer Network (NCCN), and Seattle classifications. RESULTS: PRIX 0 corresponded to 1-2% of pathologic lymph node involvement (pLN+) according to the Partin Table; PRIX 1 to 3-4%; PRIX 2 to 7-10%; PRIX 3 to 14-18%; PRIX 4 to 24-29%; PRIX 5 to 32-37%; and PRIX 6 to 42%. PRIX well separated the risks with relatively narrow ranges of probability, while D'Amico, NCCN, and Seattle classifications generally gave wide ranges especially for high-risk groups, both in the Partin Table and Kattan Nomogram. Roach's formula sometimes overestimated the risk compared to the Partin Table. CONCLUSION: PRIX fully corresponded to the Partin Table in terms of pLN+, and corresponded to the other nomograms better than any existing risk-grouping method. PRIX may thus function as a prognostic factor or contribute to patient selection in clinically localized prostate cancer. 相似文献
7.
8.
Yuhei Okubo Junji Yonese Satoru Kawakami Sinya Yamamoto Yoshinobu Komai Hideki Takeshita Yuichi Ishikawa Iwao Fukui 《International journal of urology》2007,14(9):854-855
Renal cell carcinoma (RCC) causes many kinds of symptoms such as hypercalcemia, hypertension, polycythemia and fever. Here we describe a rare case of RCC presenting with a persistent cough. After radical nephrectomy, the obstinate cough disappeared. When the tumor recurred locally, the cough also recurred. Furthermore, the cough disappeared completely again after the removal of the recurrent tumor. Although all the clinical findings suggested that the RCC caused the cough, we could not identify a specific humoral substance responsible for the cough. 相似文献
9.
Permanent prostate brachytherapy for Japanese men: Results from initial 100 patients with prostate cancer 总被引:1,自引:1,他引:0
Toshikazu Okaneya Shuji Nishizawa Tsuyoshi Nakayama Takayuki Kamigaito Iwao Hashida Noriko Hosaka 《International journal of urology》2007,14(7):602-606
OBJECTIVE: To evaluate the initial results of brachytherapy for prostate cancer with permanent iodine-125 implant in Japan. METHODS: The results obtained with brachytherapy in the initial 100 Japanese patients treated at Nagano Municipal Hospital were reviewed. Patients with a prostate-specific antigen (PSA) level of less than 10 ng/mL and a Gleason's scores of 5, 6, 3 + 4 were classified as having a low risk of recurrence. Patients with a PSA level of 10-20 ng/mL and/or a Gleason's score of 4 + 3 were classified as having an intermediate risk for recurrence. Seventy-eight of the low-risk patients and 19 of the intermediate-risk patients were treated by seed implants alone, or seed implants combined with preceding external radiation, respectively. A total of 53 patients received neoadjuvant hormone therapy. The efficacy and morbidity of brachytherapy were investigated using the serum PSA, International Prostate Symptom Score, quality of life score and uroflowmetry data. RESULTS: The average V100 and D90 obtained by post-implant dosimetry was 94.3 and 113.7%, respectively. Serum PSA decreased gradually after treatment, although it had still not reached a nadir after 1 year. There was little difference of the PSA level between the patients with and without neoadjuvant hormone therapy even at 1 year after seed implantation. There were no PSA biochemical failure or clinical recurrence during the follow-up period. Voiding symptoms worsened until 3 months after treatment, and then gradually improved. Acute urinary retention occurred transiently in one patient (1%). Rectal bleeding and severe diarrhea did not occur. CONCLUSION: Brachytherapy is a feasible and effective option for the treatment of prostate cancer in Japanese men. Brachytherapy may have a different effect in Japanese patients with respect to voiding symptoms. Urinary retention was rare, but voiding symptoms were persistent in Japanese patients. Neoadjuvant hormone therapy deserves investigation to determine whether it can achieve better results, especially in patients with an intermediate risk. 相似文献
10.